Phase I Clinical Study of AZD2171, an Oral Vascular Endothelial Growth Factor Signaling Inhibitor, in Patients With Advanced Solid Tumors
Year: 2007
Type: article
Source: Journal of Clinical Oncology
Institutions: University of Freiburg, University Medical Center Freiburg
Language: English
Subfield: Molecular Biology
Domain: Life Sciences
Keywords: AZD2171, sunitinib, VEGFR inhibitors, oral anticancer drugs, advanced solid tumors, liver metastasis, maximum tolerated dose, dose-limiting toxicity, hypertension, pharmacokinetics, pharmacodynamics, dynamic contrast-enhanced MRI, soluble VEGF receptor-2, anticancer activity, safety and tolerability
Open Access status: closed
OpenAlex ID: W2137758263
